Join IQVIA’s Launch Excellence web-series, wherein we explore the question of what it takes to achieve Launch Excellence in Oncology.
Oncology continues to be one of the growth drivers within the biopharmaceutical industry. Globally, the oncology market is forecasted to reach $440 billion by 2028, growing at 14-17% CAGR with the addition of an estimated 100 new treatments over the next 5 years. While this level of interest is evidence for large growth opportunities for global pharma companies, there are unique challenges to oncology launches that inevitably force companies to re-think launch and commercialization approach.
In this webinar, we will review key trends impacting oncology launches, explore components of a successful commercial model for oncology launch and share insights and learnings from an industry expert on successful oncology launches.
Sr. Principal, Brand and Commercial Strategy, IQVIA
Global Launch Lead Oncology, Merck KGaA
VP, Global Commercial solutions, Launch Excellence, IQVIA
Sr Consultant, EMEA Thought Leadership, IQVIA
Providing insights into oncology biomarker testing from laboratory directors' perspective
IQVIA Pipeline Link gives you access to pipeline and product launch data across 600 diseases and 80+ countries
How is Forecast Link leveraging the trend?
Understand the key changes of the IVDR and build a strategy and plan for IVDs to comply with the new requirements
IQVIA is using vast quantities of data in powerful new ways. See how we can help you tap into information from past trials, patient reported outcomes and other sources to accelerate your research.
.svg){kind=icon}
